Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research

Zacks Research upgraded shares of Aytu BioPharma (NASDAQ:AYTU) from a strong sell rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.

AYTU has been the topic of a number of other research reports. Wall Street Zen raised shares of Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Finally, Ascendiant Capital Markets upped their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.33.

Aytu BioPharma Stock Performance

AYTU stock opened at $2.61 on Monday. The firm has a market cap of $28.01 million, a P/E ratio of -0.68 and a beta of 0.35. The stock’s 50 day simple moving average is $2.53 and its 200 day simple moving average is $2.33. The company has a current ratio of 1.16, a quick ratio of 1.03 and a debt-to-equity ratio of 0.70. Aytu BioPharma has a 12-month low of $0.95 and a 12-month high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The business had revenue of $15.17 million for the quarter, compared to the consensus estimate of $12.17 million.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors have recently bought and sold shares of AYTU. Daytona Street Capital LLC acquired a new position in Aytu BioPharma during the 4th quarter valued at about $26,000. Persistent Asset Partners Ltd boosted its holdings in shares of Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after acquiring an additional 16,963 shares in the last quarter. Rothschild Wealth LLC bought a new position in shares of Aytu BioPharma in the fourth quarter valued at approximately $52,000. Bellevue Asset Management LLC acquired a new position in shares of Aytu BioPharma during the fourth quarter valued at approximately $65,000. Finally, XTX Topco Ltd bought a new stake in Aytu BioPharma during the fourth quarter worth approximately $67,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.